Opinion on R&D in Europe

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Hyundai: diesel va va voom

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

ICI: a sporting chance

Published By Datamonitor
08 Oct 2001
Expert View
Expert View

Ironing out the Glivec-glitch

Despite Novartis' chronic myeloid leukemia drug Glivec gaining fast-track approval in Europe, the National Institute of Clinical Excellence has decided to limit its use in chronic myeloid leukemia patients to the accelerated phase only, due to the lack of cost-effective data. Datamonitor's Oliver Luft investigates Glivec's costly delay and asks what can be done to prevent future hold-ups.

Published By Datamonitor
24 May 2002
Expert View
Expert View

Janssen and Eli Lilly come to blows with their antipsychotics

The war between Janssen's Risperdal and Eli Lilly's Zyprexa has been raging for several years. With the recent FDA approval of Risperdal for delaying relapse in the long-term treatment of schizophrenia, the battle could hot up. So with Lilly also having to beat off generic competition, will Zyprexa become another Prozac?

Published By Datamonitor
12 Apr 2002
CommentWire
CommentWire

John Lewis: merging dotcoms

Given that the main reason John Lewis bought Buy.com was to gain its technology, the move is hardly unexpected. It should strengthen John Lewis's online brand and increase Johnlewis.com's site traffic - both sensible objectives. However, Johnlewis.com's limited range of technology products will drive away some of Buy.com's customers.

Published By Datamonitor
22 Jan 2002
CommentWire
CommentWire

KPN Mobile: the second coming isn't pre-paid

While i-mode is being hailed as the 'second coming' for European mobile data services, various obstacles may deter its uptake. In particular, KPN is not rolling out a pay-as-you-go service - instead, it requires a subscription. This is likely to deter young users, whose viral marketing has been one of the factors driving the service's Japanese success.

Published By Datamonitor
17 Apr 2002
CommentWire
CommentWire

L'Oreal: looking pretty

Despite a weaker than expected Q4, due to the euro changeover and September 11, L'Oreal's global reach and product portfolio has brought good overall 2001 results. Its acquisition of BioMedic, meanwhile, will help sustain strong growth in the active cosmetics division through 2002. This should make L'Oreal a leading player in the emerging skincare cosmeceutical market.

Published By Datamonitor
24 Jan 2002
CommentWire
CommentWire

Liberate: a Two Way bet on enhanced programming

Liberate 1.2 includes enhanced programming software from Two Way TV, allowing TV operators to link interactive services directly to scheduled programs. Since enhanced programming is likely to be a major driver of iTV usage, middleware vendors must either develop proprietary solutions in this area, or rapidly integrate third party technologies to avoid delays to roll-out.

Published By Datamonitor
24 Apr 2002
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.